Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Initiates Coverage On Oatly Group with Perform Rating

Oppenheimer analyst Rupesh Parikh initiates coverage on Oatly Group (NASDAQ:OTLY) with a Perform rating.

byBenzinga Newsdesk

June 14, 2021

1 minute read

Oppenheimer analyst Rupesh Parikh initiates coverage on Oatly Group (NASDAQ:OTLY) with a Perform rating.

Stephens & Co. Upgrades MSC Industrial Direct Co to Overweight, Announces $115 Price Target

By Benzinga Newsdesk

Today, 9:27 AM

Stephens & Co. analyst Tommy Moll upgrades MSC Industrial Direct Co (NYSE:MSM) from Equal-Weight to Overweight and announces $115 price target.

MSM

Precision Drilling Q4 EPS $0.27 Misses $3.21 Estimate, Sales $510.50M Beat $360.68M Estimate

By Benzinga Newsdesk

Today, 9:27 AM

Precision Drilling (NYSE:PDS) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $3.21 by 91.59 percent. This is a 116.56 percent increase over losses of $(1.63) per share from

PDS

Novamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To Shareholders

By Fermin Orgambide

Today, 9:27 AM

June 8, 2022 marks a turning point for both Numinus (OTCQX: NUMIF) and Novamind (OTCQB: NVMDF).

BNOX

Credit Suisse Initiates Coverage On eFFECTOR Therapeutics with Outperform Rating, Announces Price Target of $20

By Benzinga Newsdesk

Today, 9:27 AM

Credit Suisse analyst Judah Frommer initiates coverage on eFFECTOR Therapeutics (NASDAQ:EFTR) with a Outperform rating and announces Price Target of $20.

EFTR

Oppenheimer Initiates Coverage On Oatly Group with Perform Rating

Related Posts

Stephens & Co. Upgrades MSC Industrial Direct Co to Overweight, Announces $115 Price Target

Precision Drilling Q4 EPS $0.27 Misses $3.21 Estimate, Sales $510.50M Beat $360.68M Estimate

Novamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To Shareholders

Credit Suisse Initiates Coverage On eFFECTOR Therapeutics with Outperform Rating, Announces Price Target of $20